PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from Pakistan, Bangladesh and Vietnam

Selling into Europe as a biologics and biosimilars maker from Pakistan, Bangladesh and Vietnam

Your dossier clears European validation first time, and your launch date holds.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Pakistan, Bangladesh and Vietnam, Biologics and biosimilarswho it is written for

Why this training matters

Your biosimilar dossier reaches the European Medicines Agency and fails technical validation on a structure error in Module 3. The review clock never starts. Your team rebuilds files for weeks while a competitor's biosimilar wins the first hospital tenders.

What changes after this course

Your team files an electronic Common Technical Document that is built right, and answers the day 120 list of questions from the dossier itself. You hold a certificate per learner and a training record per person, ready for the next audit or partner review.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs specialist opens Regulation (EC) No 726/2004, finds the Annex, and settles the route in one meeting instead of three. Biotechnology-derived products go to the centralised procedure, so the decentralised debate ends. The team plans the filing around the European Medicines Agency timetable, and around the European applicant you need, from day one.

Dossier writers build Module 3 to EudraLex Volume 2 and the International Council for Harmonisation Common Technical Document layout, with cell bank history and purification steps placed where the quality assessor looks. Nobody rewrites files at the last minute. The sequence reaches the eSubmission Gateway with valid folders, and the review clock starts on the date you planned.

At day 120 the Committee for Medicinal Products for Human Use adopts its list of questions, and your clinical and non-clinical leads already hold the answers. They know which immunogenicity and pharmacokinetic data the rapporteur reads first, and which comparability argument closes an objection. Replies go out from the dossier, not from memory.

Commercial leads set the launch price knowing which countries reference which. Before the first reimbursement file, they know what health technology assessment bodies expect for a biosimilar. The quality head meets the inspector with Annex 2 of EudraLex Volume 4 already applied, and the importing Qualified Person certifies batches without chasing the site for missing records.

Who needs this training

  • Regulatory Affairs Manager

    Your sequence fails technical validation on a folder error and the review clock does not start. After this course your team checks structure against the European rules before anyone presses send.

  • Head of Research and Development

    The day 120 list of questions asks for more immunogenicity data than your file holds. Your team builds Modules 2, 4 and 5 to answer those questions before the assessor asks them.

  • Quality Assurance Director

    A European inspector asks for cell line records on the first morning, and your site outside the Union has to produce them. You match your quality system to Annex 2 of EudraLex Volume 4 beforehand.

  • Head of Pharmacovigilance

    Your European partner asks who holds the Risk Management Plan and who reports serious reactions. You answer from Good Pharmacovigilance Practices Module V and your named Qualified Person for pharmacovigilance.

  • Commercial Director for Europe

    A payer asks what justifies your biosimilar's price, and the answer shapes the price in the next country too. You arrive with the clinical evidence and a launch order that protects the reference price.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: Pakistan, Bangladesh and Vietnam

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Decide from the Annex of Regulation (EC) No 726/2004 whether your biological product must use the centralised procedure.
  2. Arrange Module 3 sections for a biologic so cell bank, process validation and specification evidence sit where assessors look.
  3. Write a Module 2.4 non-clinical overview that states when a risk-based justification replaces animal studies.
  4. Set out a stepwise comparability exercise against the reference product under the European Medicines Agency guideline on similar biological medicinal products.
  5. Check an electronic Common Technical Document sequence against validation rules before uploading it through the eSubmission Gateway.
  6. Draft a Risk Management Plan section that follows Good Pharmacovigilance Practices Module V.
  7. Build a clinical evidence summary that a health technology assessment body can read before a reimbursement meeting.

What the company gets

  • Your applications reach the start of review instead of stopping at technical validation, so planned launch dates rest on the filing date you set.
  • Your regulatory team answers the day 120 list of questions from documents already in the dossier, without calling the plant for data.
  • Your quality unit hands a European inspector orderly cell line and batch records, and your importing Qualified Person has what is needed to certify each batch.
  • Your commercial team enters each country's pricing talks with a launch order and an evidence pack that protect the reference price.
  • Each learner holds a certificate and a training record, so you can show an auditor or a European partner who was trained and when.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Pick the European markets where your biologic sells first

    • Why the first country you launch in sets the reference price for the countries after it.
    • How to check the public assessment reports for rivals already approved in your class.
    • Why your applicant must be established in the European Economic Area, and what that means for partners.
  2. 2Apply Regulation (EC) No 726/2004 to decide your pipeline's route

    • How to read the Annex of Regulation (EC) No 726/2004 and tell in minutes if your product must go central.
    • What to do when your product sits outside the Annex and the route is not obvious.
    • Who rules on your file: the Committee for Medicinal Products for Human Use gives an opinion, then the European Commission decides.
  3. 3Choose the marketing authorization procedure that fits your product

    • Why the decentralised and mutual recognition routes are closed to a product listed in the Annex.
    • When the centralised route is optional for your product and when it is not.
    • How to book the pre-submission meeting with the European Medicines Agency and what to bring to it.
  4. 4Build a Module 3 that survives European quality assessors

    • How to document cell bank history so the quality assessor finds no gap to ask about.
    • The process validation evidence that Module 3 needs, set out in the Common Technical Document layout.
    • What to do when your drug substance specification does not match the data in your batch records.
  5. 5Structure Modules 2 and 4 so non-clinical questions stay closed

    • How to write the Module 2.4 overview so it points the assessor straight to the Module 4 study.
    • When a risk-based argument can replace animal studies for a biosimilar, and how to word it.
    • Why a missing toxicology endpoint comes back as a question at the day 120 clock-stop.
  6. 6Format Modules 2 and 5 so clinical assessors find answers fast

    • How to lay out Module 2.5 and Module 5 so the clinical assessor finds the pivotal study in one pass.
    • The immunogenicity data that European assessors read first, and how to present it.
    • What your pharmacokinetic comparison against the reference product must show before you file.
  7. 7Prove biosimilarity the way European Medicines Agency guidelines expect

    • How to run the stepwise comparability exercise in the guideline on similar biological medicinal products.
    • When a reference product bought outside Europe needs a bridge to the one authorised in Europe.
    • Why an unexplained purity difference draws a major objection, and how to explain it first.
  8. 8Submit an electronic Common Technical Document that passes validation

    • The folder and file rules that stop technical validation findings before a reviewer opens Module 1.
    • How to send the sequence through the eSubmission Gateway or Web Client without a failed upload.
    • What belongs in Module 1 for a central filing, from the application form to the product information.
  9. 9Answer European Medicines Agency questions inside the clock-stop

    • How to plan the answers for the day 120 list of questions while the review is still running.
    • When to ask for a longer clock-stop and when to answer in the time you have.
    • How to answer a rapporteur with data already in the dossier, so one question does not become three.
  10. 10Keep your pharmacovigilance system inspection-ready after launch

    • The deadlines for reporting serious adverse reactions that your safety team must meet in the Union.
    • How to write a Risk Management Plan to Good Pharmacovigilance Practices Module V standards.
    • Why a pharmacovigilance Qualified Person based in the European Economic Area must be named at filing.
  11. 11Meet European Good Manufacturing Practice at your site outside the Union

    • Why Annex 2 of EudraLex Volume 4 is the yardstick for your cell line and bioreactor records.
    • How the Qualified Person confirms that a batch made outside the Union meets Good Manufacturing Practice.
    • What to do when an inspection finds a major deficiency, before the finding reaches your filing.
  12. 12Plan health technology assessments and pricing before you launch

    • Why each member state prices your biosimilar on its own rules, and how to plan for that.
    • The clinical evidence that health technology assessment bodies ask for before they agree to pay.
    • Why a low launch price in one country pulls down the price in the countries that reference it.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Pakistan, Bangladesh and Vietnam, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team